European Journal Of Haematology · 1988 · 24 citations · 11 references
MedicinePharmacologyPharmacotherapyBiochemical PharmacologyClinical PharmacologyPharmacodynamicsAntiplatelet TherapyPlatelet ActivationPlatelet AggregationPlatelet FunctionPlatelet PhysiologyAdenosine Diphosphate-induced Platelet AggregationAntiplatelet DrugsCollagen-induced Platelet AggregationPlatelet Aggregation InhibitionPlatelet Function ModulationPlatelet InhibitionThromboxane BiosynthesisWhole Blood Collection
A study was made on the inhibitory effect of triflusal (600 mg/d X 15) and acetylsalicylic acid (ASA, 400 mg/d X 15) on platelet aggregation in whole blood (WB) and platelet-rich plasma (PRP) induced by ADP (2.5 mumol/l), adrenaline (50 mumol/l), collagen (1 microgram/ml) and arachidonic acid (0.8 mmol/l), in 30 insulin-dependent diabetic patients without vascular complications. Determination was also made of the serum levels of thromboxane B2 (TxB2) and of the plasma levels of 6-keto-PGF1-alpha and of beta-thromboglobulin (B-TG). Both drugs exhibited higher inhibitory effects in WB than in PRP. In WB, a significant difference between triflusal and ASA was observed against ADP-induced aggregation (67% and 46% inhibition respectively, p less than 0.01). Both drugs strongly inhibit the formation of TxB2 in serum (85% and 99%, respectively). Triflusal does not significantly change the plasma levels of 6-keto-PGF1-alpha; ASA, by contrast, causes reduction of over 95% in those plasma levels. The plasma levels of B-TG were not modified by either of the drugs.
11
Increased platelet thromboxane synthesis in diabetes mellitus.
Perry V. Halushka, Richard C. Rogers, C B Loadholt et al. · PubMed · 1981 · 257 citations
Medicine, Biochemistry, Hematology +11
Radioimmunoassay for Thromboxane B<sub>2</sub>
Elisabeth Granström, H. Kindahl, Bengt Samuelsson · Analytical Letters · 1976 · 190 citations
Medicine, Hematology, Hemostasis +16